ISRCTN84188565已完成未知
Conservative iron chelation as a disease-modifying strategy in Parkinson's disease
Centre Hospitalier Regional Universitaire de Lille0 个研究点目标入组 372 人开始时间: 2017年7月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 372
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36449420/ (added 03/10/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult patients aged 18 and older
- •2. Parkinson’s disease diagnosed according The Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s Disease (PD)
- •3. Treatment-naïve, i.e. the best population for assessing a disease-modifying effect without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa, anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain stimulation)
- •4. Patients covered by a Health Insurance System in countries where required by law
- •5. Written informed consent dated and signed prior to the beginning of any procedures related to the clinical trial
排除标准
- •1. Disease duration greater than 18 months
- •2. Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy
- •3. Subject with handicap required dopaminergic treatment at the inclusion and therefore likely not to bear 9 months without symptomatic treatment
- •4. Hoehn and Yahr stage 3 or more
- •5. Significant cognitive impairment (a Mini Mental State Examination score <24 or an equivalent impairment on a similar scale) or dementia diagnosed in accordance with the Movement Disorders Society criteria (Emre et al., 2007)
- •6. Atypical or secondary parkinsonism (supranuclear palsy, multisystem atrophy, etc.) or anomalies on MRI suggestive of vascular involvement or significant cortical or subcortical atrophy (i.e. atypical for PD)
- •7. Progressing axis I psychiatric disorders (psychosis, hallucinations, substance addiction, bipolar disorder, or severe depression), in accordance with the Diagnostic and Statistical Manual of Mental Disorders
- •8. Subjects undergoing brain stimulation
- •9. Due to the high risk of agranulocytosis caused by the IMP and the unknown mechanism by which this agranulocytosis is induced, it is not allowed to combine deferiprone with other medicinal products causing agranulocytosis (as described in the IB). Such medicinal products are the already mentioned clozapine and also some NSAIDs (e.g. phenylbutazone or metamizole), antithyroid agents, sulphonamide antibiotics or methotrexate
- •10. A history of relapsing neutropenia
- •11. Hypersensitivity to deferiprone
- •12. Patients with agranulocytosis or with a history of agranulocytosis
- •13. Patients taking a treatment at risk of agranulocytosis (clozapine, Closaril®/Leponex®)
- •14. Patients with anaemia (regardless of the latter's aetiology) or a history of another haematological disease. Haemochromatosis is not an exclusion criterion
- •15. Pregnant or breastfeeding women or women of childbearing potential not taking highly effective contraception
- •16. Kidney or liver failure
- •17. Other serious diseases
- •18. Inability to provide informed consent
- •19. Participation in another clinical trial within 3 months prior to inclusion in the study
- •20. Patient who has suffered mild or moderate depressive episode and isn’t in remission and on a stable medication for at least 8 weeks
- •Exclusion criteria for the biomarker study and the ancillary study:
- •1. Subjects for whom MRI is contraindicated (metal objects in the body, severe claustrophobia, pacemaker, incompatible surgical material)
- •2. Very severe rest tremor, which could induce MRI artefacts
- •3. Lumbar puncture
- •4. Blood coagulation disorders, antiplatelet drugs or anticoagulants
- •5. Intracranial hypertension
- •6. Contraindications to nitrous oxide
- •7. Ventilation with FiO2 >50%, emphysema or pneumothorax
- •8. Altered states of consciousness, non-cooperative patient (need to stop the nitrous oxide)
研究者
相似试验
已完成
2 期
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseParkinson DiseaseNCT02655315University Hospital, Lille372
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson’s diseaseDe Novo Parkinson’s diseaseEUCTR2015-003679-31-FRCentre Hospitalier Régional et Universitaire de Lille338
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson?s diseaseDe Novo Parkinson?s diseaseMedDRA version: 18.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-003679-31-ESCentre Hospitalier Régional et Universitaire de Lille338
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson’s diseaseEUCTR2015-003679-31-NLCentre Hospitalier Régional et Universitaire de Lille338
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson’s diseaseEUCTR2015-003679-31-CZCentre Hospitalier Régional et Universitaire de Lille338